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In utero sensitization to infectious pathogens can establish immunological memory and may influence the
immune response to unrelated antigens. Little is known about the influence of intrauterine human immuno-
deficiency virus (HIV) exposure on the cellular immune response to mycobacterial antigens. Whole-blood
culture gamma interferon (IFN-) production in response to mycobacterial antigens was measured at birth
and 6 weeks of age to determine the characteristics of the IFN- response in HIV-exposed infants to Myco-
bacterium bovis BCG and mycobacterial antigens. At birth, we observed an increased immune activation in
response to phytohemagglutinin among HIV-exposed, uninfected infants. In a proportion of these infants, we
also observed an increased immune activation in response to purified protein derivative, BCG, and early
secreted antigen target 6. Increases in the IFN- response to the four antigens between birth and 6 weeks of
age, observed in all HIV-unexposed infants, was absent in a substantial proportion of HIV-exposed, uninfected
infants. The immunological differences persisted at 6 weeks of age, suggesting a sustained impact of in utero
immune priming by HIV. Intrauterine exposure to HIV affects the infants’ cellular immune response to
mycobacterial antigens, either specifically or as a consequence of nonspecific, broadly reactive immune
activation. Further studies will be important to help determine optimal vaccination and disease prevention
strategies for this vulnerable population group.
Every year, an estimated two million infants are exposed in
utero to human immunodeficiency virus type 1 (HIV-1). Of
these, 1.5 million are HIV uninfected and approximately
700,000 acquire HIV (2). At least 90% of these children live in
sub-Saharan Africa.
Immunological changes associated with intrauterine HIV
exposure have been described in HIV-uninfected infants born
to HIV-infected mothers. HIV-specific cellular immune re-
sponses can be elicited among a proportion of these infants
(11). Reduced interleukin-12 and interleukin-2 production in
response to Staphylococcus aureus Cowan and phytohemagglu-
tinin (PHA) stimulation suggests immunosuppressive effects of
in utero HIV exposure (3, 16). An increase in activated (CD4
HLA-DR CD38) and memory (CD4 CD45RA RO)
lymphocytes suggests in utero antigenic stimulation of CD4
lymphocytes related to HIV products or antigens associated
with opportunistic pathogens (16).
The immunological differences observed in HIV-exposed,
uninfected infants are especially noteworthy given the imma-
turity of the neonatal cellular immune response (1). Immature,
naive lymphocytes are the dominant lymphocyte phenotypes in
infants (16). These naive cells are, compared to memory T
cells, deficient in producing gamma interferon (IFN-) (5).
Furthermore, neonatal T cells respond weakly to antigen-pre-
senting cells, resulting in further decreased IFN- production
(3, 19, 20). This low IFN- production may result in increased
susceptibility to intracellular pathogens, including Mycobacte-
rium tuberculosis (15).
In this study, we aimed to investigate the immune cytokine
(IFN-) response to mycobacterial antigens and Mycobacte-
rium bovis BCG vaccine among infants exposed to HIV in
utero. In addition, we investigated the maturation of the cel-
lular immune response of these infants in the first 6 weeks of
life.
MATERIALS AND METHODS
Study participants. We enrolled 120 HIV-infected and 13 HIV-uninfected
mothers and their infants between 19 January 2003 and 25 March 2003 at the
Chris Hani Baragwanath Hospital in Soweto, South Africa. All of the women
took part in the prevention of mother-to-child HIV transmission (PMTCT)
program and had a known HIV infection status prior to enrollment. Infants with
a birth weight of less than 2,500 g or with medical problems at birth were
excluded. Clinical information, including HIV status, administration of nevirap-
ine to mother and infant, history of active tuberculosis before and during preg-
nancy, and history of contact with active tuberculosis during pregnancy, was
obtained with a structured questionnaire at the time of enrollment. Infants were
followed up at 6, 10, and 14 weeks to collect data on feeding (exclusive breast-
feeding, mixed feeding, or formula), occurrence of fever, development of a BCG
scar (noted as papules, an ulcerating lesion, swollen axillary lymph nodes, and flat
or healed), and contact with active tuberculosis.
Peripheral blood samples from the mother (at delivery) and infant (at day 1
and week 6) were collected in preservative-free Na-heparin Vacutainer tubes and
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processed within 3 h of collection. Blood was collected for maternal CD4 cell
counting and PCR determination of infant HIV infection status at day 1 and
week 6.
Written informed consent was obtained for participation of the mothers and
their infants. Ethical approval was obtained from the Committee for Research on
Human Subjects of the University of the Witwatersrand and the Institutional
Review Board of the University of North Carolina.
Production of cytokines. We preferred the use of a whole-blood assay over
alternative assays, such as the lymphocyte proliferation assay and cytokine de-
tection with purified peripheral blood monocyte cultures because of its relative
simplicity and the smaller amount of blood required from neonates. Others have
demonstrated that IFN- responses to mitogenic stimuli can be effectively de-
tected with a whole-blood assay and may even be more reflective of the in vivo
situation (10, 17). It has also been shown that the whole-blood assay is sensitive
and specific for detecting mycobacterium-specific immunity after BCG vaccina-
tion of infants residing in developing countries (8).
Whole blood was collected by venipuncture in a sterile nonpretreated plastic
tube and immediately mixed with sterile sodium heparin at a concentration of 10
U/ml. The blood was further diluted 1/10 with sterile RPMI 1640 tissue culture
medium containing 10 ml of L-glutamine and 100 mg of penicillin G-streptomy-
cin sulfate. Diluted blood (180 l per well) was dispensed into 96-well tissue
culture plates within 3 h of collection. Cultures were stimulated with 20 l of
mitogen per well to give a final concentration of 5 g/ml PHA, 10 g/ml purified
protein derivative (PPD 289; Ministry of Agriculture Fisheries and Food, Central
Veterinary Laboratory, New Haw, Addlestone, Surrey, United Kingdom), 2.5
g/ml early secreted antigen target 6 (ESAT-6) [recombinant ESAT-6 isolated
from Escherichia coli strain BL21(DE3)/pLysS, donated by Colorado State Uni-
versity], or 15 g/ml live attenuated BCG (Danish strain 331; Statens Serum
Institut, Copenhagen, Denmark). Cultures were stimulated at 37°C in 5% CO2
for 3 days with PHA and for 7 days with BCG, PPD, or ESAT-6. Supernatants
were harvested from the wells and stored at 70°C before cytokine analysis.
IFN- production was measured by enzyme-linked immunosorbent assay
(ELISA) with pairs of monoclonal antibodies (PharMingen, San Diego, Califor-
nia). All procedures were performed according to manufacturer’s instructions.
The detection limit for the ELISAs was 5 pg/ml.
Statistical analysis. The IFN- response was calculated as the amount of
IFN- production in response to the stimulus (i.e., PHA, PPD, ESAT-6, and
BCG) minus the amount of IFN- production in the absence of a stimulus and
then log transformed. Infants exposed to HIV in utero were classified as either
having an IFN- response pattern similar to the response observed in HIV-
unexposed infants (group 1) or different from the response observed in HIV-
unexposed infants (group 2). The IFN- responses defining the group 2 response
patterns were determined at the time of data analysis as follows: for PHA, a
response at birth of 2.3 log units or a response at 6 weeks less than or equal to
the response at birth; for PPD and ESAT-6, a response at birth of 0; and for
BCG, a response at birth of 0.33 log units. These cutoff values were selected
after the initial analysis, were based on the distributions observed in scatter plots
detailing the responses among HIV-unexposed infants, and ensured that all
HIV-unexposed infants would fall into the group 1 response category.
The Wilcoxon rank sum test for dependent samples and the Mann-Whitney
tests for independent samples were used to test differences in the median log
IFN- responses between groups. The Student t test was used to compare means
and Fisher’s exact test to compare proportions between groups. All statistical
analyses were performed with SAS version 8.2 (Cary, NC, 2001) and SPSS 10.0
(Chicago, IL, 1999).
RESULTS
One hundred thirty-three mother-infant pairs were enrolled.
The first five mother-infant pairs were excluded from the anal-
ysis as their samples were used in the assay optimization pro-
cess. Of the remaining 128 mother-infant pairs, 18 were ex-
cluded from the analysis because of loss of follow-up (seven
mothers had relocated, three babies and one mother had died,
two mothers withdrew, and five were untraceable). Four in-
fants were HIV positive on PCR analysis at 6 weeks; no infants
seroconverted between 6 and 14 weeks of age. The four HIV-
infected infants and their mothers were also excluded from the
analysis. Of the final 106 mother-infant pairs included in the
analysis, 94 mothers were HIV infected and 12 mothers were
HIV uninfected.
The level of immunosuppression among participating
women was comparable to that described in other studies (6,
7): 12% had CD4 cell counts of 200, 14% had CD4 cell
counts between 200 and 350, 27% had CD4 cell counts be-
tween 350 and 500, and 47% had CD4 cell counts of 500.
Eighty-nine percent of the HIV-infected women and 90% of
the HIV-exposed infants received nevirapine for PMTCT.
All of the infants enrolled in this study were vaccinated with
BCG on day 1, and all developed a BCG scar, 96% by 6 weeks
of age, 99% by 10 weeks of age, and 100% by 14 weeks of age.
Comparisons of median IFN- production in PHA-, PPD-,
BCG-, and ESAT-6-stimulated whole-blood cultures. The
amount of in vitro IFN- production in supernatants was com-
pared among four groups: infants born to HIV-infected moth-
ers, infants born to HIV-uninfected mothers, HIV-infected
mothers, and HIV-uninfected mothers. Unstimulated whole-
blood samples (negative controls) produced undetectable or
small amounts of IFN-. The mean background unstimulated
IFN- production was higher in HIV-infected or -exposed in-
dividuals: 5.3 pg/ml and 0.62 pg/ml for HIV-infected and -un-
infected mothers (P  0.02); 31.1 pg/ml and 0 pg/ml for HIV-
exposed and HIV-unexposed infants at birth (P  0.01); and
105.9 pg/ml and 55.9 pg/ml for HIV-exposed and HIV-unex-
posed infants at 6 weeks of age (P  0.49). The median log
IFN- production in supernatants of whole-blood cultures
stimulated with PHA, PPD, BCG, and ESAT-6 was signifi-
cantly lower in infants at birth compared to mothers and sig-
nificantly higher in infants at 6 weeks of age compared to
infants at birth (Fig. 1; Table 1). When we compared the
immune responses of infants at 6 weeks of age and those of
their mothers, we found that the median infant log IFN-
production at 6 weeks was significantly lower for PHA (P 
0.01) whereas the response to BCG at 6 weeks of age among
HIV-exposed infants was higher compared to their mothers’
IFN- response to BCG (P  0.001) (Fig. 1; Table 1).
The median log IFN- production tended to be lower in
HIV-infected compared to HIV-uninfected mothers and HIV-
exposed compared to HIV-unexposed infants at 6 weeks of
age. In contrast, the median IFN- production in response to
PHA at birth was higher among HIV-exposed compared to
HIV-unexposed infants (Fig. 1).
Correlation between maternal and infant IFN- production.
Correlations between maternal and neonatal IFN- produc-
tion were poor, with Spearman correlation coefficients (r val-
ues) of 0.13, 0.14, 0.19, and 0.27 for IFN- production in
response to stimulation of whole-blood cultures with PPD,
PHA, ESAT-6, and BCG, respectively. When investigating
these correlations stratified by maternal HIV infection status,
the r values were slightly higher for HIV-infected mothers and
their HIV-exposed infants but correlations remained poor (r 
0.16, 0.25, 0.27, and 0.32 for PPD, ESAT-6, PHA, and BCG,
respectively).
Poor correlations were also observed when comparing
IFN- production between infants at birth and at 6 weeks of
age (r values of 0.15, 0.07, 0.16, and 0.08 for PPD, PHA,
ESAT-6, and BCG, respectively).
Intraindividual correlations between IFN- responses to
PHA, PPD, ESAT-6, and BCG. In mothers, moderate correla-
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tion coefficients were found between IFN- production in re-
sponse to ESAT-6 and that in response to PPD (r  0.64, P 
0.001, for HIV-infected mothers and r  0.56, P  0.01, for
HIV-uninfected mothers) and between IFN- production in
response to PPD and that in response to BCG (r  0.55, P 
0.001, for HIV-infected mothers and r  0.40, P  0.1, for
HIV-uninfected mothers). All other correlations were poor.
In infants at birth, the highest correlation coefficient was
obtained between IFN- production in response to PPD and
that in response to ESAT-6 (r  0.61, P  0.001). In infants at
FIG. 1. IFN- production in stimulated cultures of whole blood from HIV-infected mothers (Mom; n  94) and HIV-uninfected mothers (n
 12) at delivery and in HIV-exposed, uninfected infants (n  94) and HIV-unexposed infants (n  12) at birth and 6 weeks of age. Box plots
represent log IFN- production, measured by ELISA, in whole-blood cultures stimulated at 37°C in 5% CO2 by PHA (5 g/ml for 3 days), PPD
(10 g/ml for 7 days), ESAT-6 (2.5 g/ml for 7 days), or BCG (15 g/ml for 7 days). The population is stratified by maternal HIV status. The first
of each pair of box plots represents values in HIV-uninfected mothers and children born to HIV-negative mothers; the second box of each pair
of box plots represents values in HIV-infected mothers and children born to HIV-infected mothers. The horizontal bars inside the boxes
correspond to the median (50th percentile), the box limits correspond to the 25th and 75th percentiles, the vertical bars correspond to the 10th
and 90th percentiles, outliers (cases whose value is 1.5 to 3 box lengths beyond the interquartile range) are plotted as points, and extreme values
(cases whose value is 3 box lengths beyond the interquartile range) are plotted as asterisks.
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6 weeks of age, the strongest correlation was observed between
IFN- production in response to PPD and that in response to
BCG (r  0.76, P  0.001), an indication of the immune
response developed upon BCG vaccination.
Response to BCG vaccination and maturation of infant cy-
tokine (IFN-) production. We observed that in HIV-unex-
posed infants, IFN- production in response to different anti-
gens increased significantly from birth to 6 weeks of age,
reflecting maturation of the cellular immune response (PHA)
and immune response to BCG vaccination (PPD and BCG)
(Fig. 2). Overall, IFN- production among HIV-exposed in-
fants increased significantly for PPD and BCG and tended to
increase for ESAT-6 and PHA. HIV-exposed infants could be
categorized into two groups based on the pattern of change in
the immune response from birth to 6 weeks of age. In one
group (group 1), the change in IFN- production over time was
similar to that of HIV-unexposed infants: an undetectable
IFN- response at birth for PPD and ESAT-6 or a low IFN-
response at birth (0.33 log units for BCG and 2.3 log units
for PHA), followed by an increase in the IFN- response at 6
weeks of age. The immune response in the other group of
HIV-exposed infants (group 2) was characterized by a positive
IFN- response at birth (2.3 log units for PHA, 0.33 log
units for BCG, and 0 for PPD and ESAT-6) and a level of
IFN- production at 6 weeks of age that was either moderately
increased, similar to, or decreased relative to the amount of
IFN- produced at birth (Fig. 2). The proportion of HIV-
exposed infants belonging to one of these two groups was
different for each of the stimuli investigated. The proportions
of HIV-exposed infants classified in group 2 were 63, 45, 21,
and 20% for the IFN- responses to PHA, BCG, ESAT-6, and
PPD, respectively. While 32% of the infants were classified as
group 2 for at least one of the four stimuli investigated (PHA,
PPD, ESAT-6, or BCG), only 10% of the children were clas-
sified as group 2 for all four stimuli. The limited overlap of
infants classified as having a group 2 response to different
stimuli makes anergy to all stimuli in a subgroup of infants an
unlikely explanation for the observed phenomenon.
We examined whether certain exposure variables may be
responsible for the observed differential changes over time
(birth to 6 weeks of age) in the infants’ ability to produce
IFN- in response to PHA or mycobacterial antigens. No sig-
nificant differences between the groups could be identified for
the maternal CD4 count, a history of maternal exposure to
active tuberculosis during pregnancy, maternal and infant ex-
posure to nevirapine for PMTCT, or continued exposure to
HIV through breastfeeding (Table 2).
DISCUSSION
Immunological memory can be established by in utero prim-
ing of T cells, and the immune environment established by in
utero sensitization to specific antigens can influence immunity
to unrelated antigens. In particular, Malhotra et al. demon-
strated that cytokine responses engendered by in utero sensi-
tization to filariae affects the cellular immune response to PPD
(12). It has been suggested by Rich et al. that the increased
immune activation documented in HIV-exposed, uninfected
infants may be the result of in utero exposure to HIV antigens
and/or exposure to antigens related to other infections in their
HIV-infected mothers (16). In this study, we aimed to inves-
tigate the immune cytokine (IFN-) response to mycobacterial
antigens and BCG vaccine among infants exposed to HIV in
utero and the maturation of the cellular immune response of
these infants in the first 6 weeks of life.
IFN- production in response to stimulation with PHA mi-
togen and mycobacterial antigens was significantly lower in
infants at birth compared to that in mothers, supporting the
well-established immature status of the neonatal immune re-
sponse. Consistent with findings by Vekemans et al. (21), the
median IFN- production in response to PPD and BCG in-
creased significantly from birth to 6 weeks of age in both
HIV-exposed and -unexposed children, indicating the estab-
lishment of an immune response following BCG vaccination.
The median IFN- production in response to PHA increased
significantly from birth to 6 weeks of age, indicating maturation
of the infant’s immune response.
Similar to the observation described by Rich et al. (16), we
observed an increased level of immune activation in response
to PHA in a proportion of HIV-exposed infants at birth. In
TABLE 1. Median log IFN- production in mothers at delivery and in infants at birth and 6 weeks of age,
stratified by maternal HIV infection
Group and stimulus
Mothers Infants at birth Infants at 6 wk P value






PHA 4.42 3.81, 4.67 0.28 0.00, 1.23 3.41 2.92, 3.79 0.001 0.007 0.002
PPD 2.58 1.02, 3.24 0.00 0.00, 0.00 3.10 2.30, 3.66 0.002 0.271 0.002
ESAT-6 1.14 0.16, 2.50 0.00 0.00, 0.00 0.18 0.00, 1.02 0.002 0.144 0.028
BCG 1.83 1.37, 2.54 0.00 0.00, 0.00 2.46 2.20, 3.27 0.001 0.102 0.003
HIV-positive, exposed
PHA 4.01 3.37, 4.55 2.42 1.79, 3.09 3.13 2.20, 3.51 0.001 0.001 0.013
PPD 1.69 0.00, 2.96 0.00 0.00, 0.00 2.28 1.01, 3.05 0.001 0.165 0.001
ESAT-6 0.00 0.00, 1.27 0.00 0.00, 0.00 0.00 0.00, 0.92 0.002 0.292 0.056
BCG 1.43 0.00, 2.41 0.00 0.00, 1.13 2.34 1.30, 3.02 0.001 0.001 0.001
a IQR, interquartile range.
b Assume independent samples for the Mann-Whitney test with a nonparametric distribution.
c Assume dependent samples for the Wilcoxon signed-rank test with nonparametric distribution.
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FIG. 2. Changes in log IFN- production in stimulated cultures of whole blood from individual infants at birth (birth) and 6 weeks of age (6
weeks). Each pair of points connected by a line represents log IFN- levels for a single subject. For each stimulus investigated (PHA, PPD,
ESAT-6, or BCG), the changes over time within each subject are presented for HIV-exposed and HIV-unexposed infants separately.
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addition, we observed increased cytokine production in re-
sponse to mycobacterial antigens in a proportion of HIV-ex-
posed infants at birth, suggesting aspecific T-cell priming fol-
lowing in utero exposure to HIV. Even though the median
IFN- production in response to PHA, PPD, and BCG was
significantly higher at 6 weeks of age compared to that at birth
in the group of HIV-exposed infants as a whole, a significant
increase was absent in a substantial proportion (32%) of the
HIV-exposed, uninfected infants. This may indicate a lack of
immune response to BCG, a lack of maturation of the cellular
immune response, or a “fast-tracked” immune response in
these infants so that their immune capability at birth is com-
parable to that of a 6-week-old infant who has not been simi-
larly primed in utero. These observations suggest that immu-
nological differences observed at birth between HIV-exposed
and HIV-unexposed infants may persist for at least the first 6
weeks of life.
We were especially interested in the neonatal and infant
cellular immune response to BCG, a widely used tuberculosis
vaccine in developing countries. As tuberculosis is the most
important opportunistic pathogen in HIV-infected individuals,
HIV-exposed infants are more likely than HIV-unexposed in-
fants to be exposed to adults with active tuberculosis. A study
in The Gambia has demonstrated that 2-month-old infants
vaccinated with BCG at birth displayed strong proliferative
responses and produced high levels of IFN- in response to
PPD (13). Little information is available on the immunogenic
and protective effects of BCG in HIV-exposed infants. In this
study, we found that, in contrast to a report by Ota et al. (14),
there was no difference between the proportions of HIV-ex-
posed and -unexposed infants that develop a BCG scar, as
100% of the infants included developed a BCG scar by 14
weeks of age. There was also no significant difference in the
median IFN- response to BCG between HIV-exposed and
-unexposed infants at 6 weeks of age. In our study, the devel-
opment of an immune response to the BCG vaccine was re-
flected by the strong correlation between IFN- production in
response to PPD and BCG at 6 weeks of age, whereas at birth
the strongest correlation was obtained between IFN- produc-
tion in response to PPD and that in response to ESAT-6. An
important difference between HIV-exposed and -unexposed
infants was that in 45% of the HIV-exposed, uninfected in-
fants, an IFN- response to BCG was already present at birth
and did not increase subsequent to BCG vaccination. These
findings may have important implications for the optimal tim-
ing and effectiveness of BCG vaccination in these infants and
warrant careful immunological evaluation of new tuberculosis
vaccines.
This study has several limitations. The short duration of
follow-up of infants precluded the possibility of exploring the
long-term effect of in utero exposure to HIV on the cellular
immune response to mycobacterial antigens. The lack of data
on intraindividual assay variability may have led to misclassi-
fication bias in some cases. The study could not determine the
functional implication of the findings, i.e., the protective effect
of BCG vaccination in HIV-exposed infants. The disadvantage
of using a whole-blood assay was that we could not identify the
cell types responsible for the increased IFN- production seen.
While CD4 lymphocytes are the main source of IFN- in
response to PPD (21), up to 20% of IFN--producing lympho-
cytes in the PPD-stimulated blood of infants and children are
NK cells (8). We can therefore only hypothesize that the ob-
served immune activation at birth in HIV-exposed, uninfected
infants is due to aspecific T-cell priming following in utero HIV
exposure. Several alternative explanations exist. HIV-infected
women may have subclinical tuberculosis, leading to in utero
exposure to mycobacterial antigens and development of a spe-
cific memory response in their infants (4, 18). Mycobacterium-
specific responses, undetectable in the absence of exposure to
HIV-1, could be “unmasked” in the presence of priming by
HIV-1 in utero. Maturation stages of monocytes or other an-
tigen-presenting cells could be different in these children. Non-
specific priming could lead to IFN- production by cells other
than T cells, such as NK cells (8). Cross-reactivity between
HIV-1 and mycobacterial antigens may also have led to the
observed immune activation (9).
Due to these study limitations, it remains unclear whether
the higher IFN- response to mycobacterial antigens observed
in HIV-exposed newborns represents nonspecific activation or
in utero exposure to mycobacterial antigens. The study led to
some interesting results that will allow hypothesis generation
which can lead to investigations to further unravel the com-
plexities. To gain further insight into the causal factors, deter-
mination of the mononuclear cell types and determination of
TABLE 2. Comparison of exposure variables among HIV-exposed, uninfected infants whose cellular immune response, measured by in vitro
IFN- production in response to PHA PPD, ESAT-6, and BCG, does (group 1) or does not (group 2) demonstrate a pattern of maturation
between birth and 6 weeks of age
Parameter
PHAa PPDa ESAT-6a BCGa
Group 1 Group 2 Group 1 Group 2 Group 1 Group 2 Group 1 Group 2
No. of infants 35 59 75 19 74 20 52 42
Mean maternal CD4 cell countb 548 570 554 593 561 565 567 556
Maternal CD4 cell count of 200 (%) 17.7 8.6 9.5 22.2 11.1 15.0 15.4 9.5
Exposure to active tuberculosis during
pregnancy (%)c
3.0 11.1 7.1 11.8 7.4 10.5 8.2 7.9
Maternal nevirapine exposure (%) 88.6 88.1 85.3 100 87.8 90.0 89.8 92.3
Infant nevirapine exposure (%)d 90.9 91.2 90.1 94.7 88.7 100 89.8 92.3
Breastfeeding (%)d 36.7 63.3 80.0 20.0 0.0 22.2a 54.4 45.6
a None of the differences were statistically significant by Fisher’s exact test.
b Missing information for two subjects.
c Missing information for seven mother-infant pairs.
d Missing information for four infants.
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IFN- production from specific cell populations would be im-
portant. A negative control such as an antigen to which the
fetus and infant are not exposed could be included to shed light
on the specificity of the response to mycobacterial antigens.
The inclusion of a control group of infants for whom BCG
vaccination was delayed to 6 weeks of age would help differ-
entiate responses due to mycobacterial exposure and BCG
vaccination.
The qualitative differences in the immune response among a
substantial proportion of HIV-exposed, uninfected infants de-
mands further study of the early life immune response in these
infants, its determining factors, and its clinical implications to
help determine optimal vaccination and disease prevention
strategies for this vulnerable population group.
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